Ketamine and
lithium both inhibit
glycogen synthase kinase 3. In addition,
lithium and
ketamine have synergistic
antidepressant-like effects at individually subeffective doses in rodents. We hypothesized that
ketamine's
antidepressant effects would be improved by therapeutic doses of
lithium versus
valproate and that serum
lithium levels would positively correlate with
ketamine's
antidepressant efficacy. Thirty-six patients with treatment-resistant
bipolar depression maintained on therapeutic-dose
lithium (n = 23, 0.79 ± 0.15 mEq/L) or
valproate (n = 13, 79.6 ± 12.4 mg/mL) received 0.5 mg/kg
ketamine infusion in a randomized, double-blind, placebo-controlled, crossover trial. The primary depression outcome measure-the Montgomery-Åsberg Depression Rating Scale (MADRS)-was assessed before infusion and at numerous postinfusion time points. Both
lithium (F 1,118 = 152.08, p < 0.001, and d = 2.27) and
valproate (F 1,128 = 20.12, p < 0.001, and d = 0.79) significantly improved depressive symptoms, but no statistically significant difference was observed between mood stabilizer groups (F 1,28 = 2.51, p = 0.12, and d = 0.60). Serum
lithium and
valproate levels did not correlate with
ketamine's
antidepressant efficacy. Although the study was potentially underpowered, our results suggest that
lithium may not potentiate
ketamine's
antidepressant efficacy in treatment-resistant
bipolar depression.